drugset / Trial / NCT01600339
A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC)
NaSingle-groupOpen-labelTreatment
Summary
In this phase II multicenter study, the investigators aim to evaluate the efficacy and tolerability of a novel taxane-cabazitaxel as single agent second-line chemotherapy for metastatic urothelial carcinoma.
Timeline
- Start
- 2012-05
- Primary completion
- 2015-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabazitaxel | Other / unclassified | 25 mg/m2 | Intravenous |